Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam.

Created on 14 Oct 2026

Authors

Khue Dang Minh Van, Han Ngoc Bao Pham, An Thi Thanh Nguyen, Nhi Truc Y Nguyen, Cam Thi Le Pham, Nhan Thi Thanh Dang, Quynh Thi Huong Bui

Published in

PloS one. Volume 21. Issue 10. Pages e0359631. Epub Oct 13, 2026.

Abstract

To assess the utilization of ceftazidime-avibactam at Thong Nhat Hospital, a national hospital in Vietnam.
A descriptive cross-sectional study was conducted using retrospective data from medical records of inpatients aged ≥ 18 years who received ceftazidime-avibactam for at least 2 days between January 2023 and March 2025 at Thong Nhat Hospital, Vietnam. The appropriateness of ceftazidime-avibactam use was evaluated based on Thong Nhat Hospital's antibiotic use guideline. The backward conditional method was used to identify factors associated with patient treatment outcomes.
A total of 101 patients were included, with a median age of 78 years (68-86). Respiratory and bloodstream infections were the most common types, accounting for 84.15% and 44.55% of cases, respectively. Gram-negative bacteria comprised 76.05% of isolates, with Klebsiella pneumoniae (26.47%), Klebsiella aerogenes (18.50%) and Pseudomonas aeruginosa (10.50%) being the most frequent. The susceptibility rate to ceftazidime-avibactam was 71.43% for Klebsiella pneumoniae, 95.65% for Klebsiella aerogenes and 42.86% for Pseudomonas aeruginosa. OXA-48 was the most detected carbapenemase gene (37.84%). The overall appropriateness rate of ceftazidime-avibactam use was 70.30%. The treatment success rate was 39.60%. Treatment in the intensive care unit was associated with decreased treatment success, while comorbid heart failure showed a potential association.
The treatment success rate with ceftazidime-avibactam in this study was relatively low. Continuous surveillance of microbiological profiles and antibiotic resistance, particularly to ceftazidime-avibactam, is essential to better guide the management of drug-resistant Gram-negative infections at the hospital.

PMID:
42868159
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement